Jos Vermylen

11.2k total citations · 1 hit paper
171 papers, 8.0k citations indexed

About

Jos Vermylen is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jos Vermylen has authored 171 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Hematology, 43 papers in Cardiology and Cardiovascular Medicine and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jos Vermylen's work include Platelet Disorders and Treatments (66 papers), Antiplatelet Therapy and Cardiovascular Diseases (34 papers) and Hemophilia Treatment and Research (30 papers). Jos Vermylen is often cited by papers focused on Platelet Disorders and Treatments (66 papers), Antiplatelet Therapy and Cardiovascular Diseases (34 papers) and Hemophilia Treatment and Research (30 papers). Jos Vermylen collaborates with scholars based in Belgium, United States and France. Jos Vermylen's co-authors include Hans Deckmyn, Marc Hoylaerts, Jef Arnout, Hugo Van Aken, Erik Vandermeulen, Kathelijne Peerlinck, Paolo Gresele, André Van Assche, Bernard Spitz and Chris Van Geet and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Jos Vermylen

166 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anticoagulants and Spinal-Epidural Anesthesia

1994 574 citations Jos Vermylen et al. profile →

Peers

Countries citing papers authored by Jos Vermylen

Since Specialization

Citations

This map shows the geographic impact of Jos Vermylen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jos Vermylen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jos Vermylen more than expected).

Fields of papers citing papers by Jos Vermylen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jos Vermylen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jos Vermylen. The network helps show where Jos Vermylen may publish in the future.

Co-authorship network of co-authors of Jos Vermylen

This figure shows the co-authorship network connecting the top 25 collaborators of Jos Vermylen. A scholar is included among the top collaborators of Jos Vermylen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jos Vermylen. Jos Vermylen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Thalamic Stimulation as a Treatment for Primary Erythromelalgia: Technical Case Report 2005 ·Operative Neurosurgery ·Hans Delye, Lieven Lagae, Jos Vermylen, Bart Nuttin	6
2	Quality assessment of oral anticoagulation in Belgium, as practiced by a group of general practitioners 2005 ·Acta Cardiologica ·Nerée Claes, Frank Buntinx, Johan Vijgen, Jef Arnout, Jos Vermylen, Steffen Fieuws, (unknown)	6
3	The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial 2005 ·European Heart Journal ·(unknown), Frank Buntinx, Johan Vijgen, Jef Arnout, Jos Vermylen, Steffen Fieuws, (unknown)	39
4	The pituitary adenylate cyclase–activating polypeptide is a physiological inhibitor of platelet activation 2004 ·Journal of Clinical Investigation ·Kathleen Freson, Hitoshi Hashimoto, Chantal Thys, Christine Wittevrongel, Sophie Danloy, Yoshiko Morita, Norihito Shintani, Yoshiaki Tomiyama, Jos Vermylen, Marc Hoylaerts, Akemichi Baba, Chris Van Geet	48
5	ATP Augments von Willebrand Factor-dependent Shear-induced Platelet Aggregation through Ca2+-Calmodulin and Myosin Light Chain Kinase Activation 2004 ·Journal of Biological Chemistry ·Cécile Oury, (unknown), (unknown), Rita De Vos, Jos Vermylen, Marc Hoylaerts	39
6	Pulmonary Inflammation and Thrombogenicity Caused by Diesel Particles in Hamsters 2003 ·American Journal of Respiratory and Critical Care Medicine ·Abderrahim Nemmar, Benoît Nemery, Peter Hoet, Jos Vermylen, Marc Hoylaerts	105
7	Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis 2003 ·Expert Review of Cardiovascular Therapy ·Arnaud Bonnefoy, Jos Vermylen, Marc Hoylaerts	19
8	The intracellular tyrosine residues of the ATP‐gated P2X₁ ion channel are essential for its function 2002 ·FEBS Letters ·Emese Tóth-Zsámboki, Cécile Oury, Hiroyuki Watanabe, Bernd Nilius, Jos Vermylen, Marc Hoylaerts	11
9	A Natural Dominant Negative P2X1 Receptor Due to Deletion of a Single Amino Acid Residue 2000 ·Journal of Biological Chemistry ·Cécile Oury, Emese Tóth-Zsámboki, Chris Van Geet, Chantal Thys, Lin Wei, Bernd Nilius, Jos Vermylen, Marc Hoylaerts	46
10	Les anomalies congénitales de la veine cave inférieure prédisposent-elles à la thrombose ? 1996 ·Sang thrombose vaisseaux ·(unknown), L Stockx, (unknown), Jos Vermylen	0
11	Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. 1996 ·Journal of Clinical Investigation ·(unknown), (unknown), H. Lenk, Jos Vermylen, Jean‐Marie Saint‐Remy	59
12	Platelet actuation 1995 ·Blood Reviews ·Daniël Blockmans, Hans Deckmyn, Jos Vermylen	207
13	An echistatin‐like Arg‐Gly‐Asp (RGD)‐containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function 1994 ·British Journal of Haematology ·Hans Deckmyn, Patrick Stanssens, Bernard Hoet, Paul Declerck, Marc Lauwereys, Yannick Gansemans, István Tornai, Jos Vermylen	32
14	Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men 1994 ·Clinical Pharmacology & Therapeutics ·Jeffrey S. Barrett, Gail Murphy, Kathelijne Peerlinck, Inge De Lepeleire, Robert J. Gould, Deborah Panebianco, Elizabeth Hand, Hans Deckmyn, Jos Vermylen, Jef Arnout	111
15	A new lupus anticoagulant neutralization test based on platelet‐derived vesicles 1992 ·British Journal of Haematology ·Jef Arnout, (unknown), M. Vanrusselt, Jos Vermylen	22
16	HIV-Related Thrombocytopenia 1992 ·Acta Clinica Belgica ·Daniël Blockmans, Jos Vermylen	4
17	TCV-309 - A NOVEL PAF-ANTAGONIST, INHIBITS PAF-INDUCED HUMAN PLATELET-AGGREGATION EXVIVO 1991 ·Thrombosis and Haemostasis ·Filip Stockmans, Jozef Arnout, Marleen Depré, Paul J. DeSchepper, (unknown), Jos Vermylen	1
18	Influence of the lupus anticoagulant on clotting tests 1990 ·Clinical Rheumatology ·Jos Vermylen, Jef Arnout	1
19	Venous thromboses in particular organs 1986 ·Journal of the American College of Cardiology ·Joachim Kienast, Jos Vermylen, Marc Verstraete	3
20	Platelet-endotoxin interaction: a review. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·N. Semeraro, D Fumarola, (unknown), Jos Vermylen	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact